Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GuardianCath for Prevention of CAUTI in Children With Neurogenic Bladder
NCT02697162Phase 3Withdrawn
- Sponsor
- Children's Hospital Zagreb
- Start
- Jun 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 3 trial of octenidine in catheter-associated urinary tract infection (CAUTI), sponsored by Children's Hospital Zagreb. Planned start Jun 2016; status: withdrawn.
02
Drugs
octenidine
03
Conditions
catheter-associated urinary tract infection (CAUTI)
Beyond the preview
Go deeper on NCT02697162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02697162.